Endocrine
Return to Library
terna Zentaris Reports Second Quarter 2009 Financial and Operating Results
2009 AUG 24 - (NewsRx.com) -- terna Zentaris Inc. (NASDAQ:AEZS)(NASDAQ:TSX:)(NASDAQ:AEZ) ("the Company"), a global biopharmaceutical company focused on endocrinology and oncology, reported financial and operating results as at and for the three-month and six-month periods ended June 30, 2009. Second Quarter 2009 Highlights April - Two poster presentations at the American Association of Cancer Research ("AACR") Annual Meeting on in vitro and in vivo results for AEZS-126 in human tumors, and one poster presentation on Phase 1 results with AEZS-112 in solid tumors or lymphoma. - Notification from Nasdaq that the Company had regained compliance with Nasdaq's minimum bid price rules. May - Presentation at the American Society of Clinical Oncology ("ASCO") Annual Meeting of results supporting evaluation of AEZS-108 in prostate cancer. June - Presentation at the ASCO Annual Meeting of positive Phase 2 data on perifosine in advanced metastatic colon cancer and advanced renal cell carcinoma by the Company's partner, Keryx Biopharmaceuticals, Inc. - Acquisition from Ardana Bioscience Ltd. of all assets relating to AEZS-130. - Disclosure of neutral results for the Company's Phase 2 trial in non-small cell lung cancer with perifosine as radioenhancer. - Announcement of the initiation of the extension of the Company's North American Phase 3 efficacy study with cetrorelix in benign prostatic hyperplasia ("BPH"). This extension of the study is sponsored by sanofi-aventis, the Company's partner for the US market. - Poster presentation at the Endocrine Society ("ENDO") Annual Meeting on AEZS-130 as a simple diagnostic test for adult growth hormone deficiency. - Announcement that data from the Company's safety study of the Phase 3 program in BPH with cetrorelix are expected to be disclosed ahead of schedule, from the fourth quarter 2009 to the third quarter of 2009. - Completion of a registered direct offering of US$10 million of units comprised of common shares and common share purchase warrants to certain institutional investors. Subsequent to Quarter-End July - Publication in Proceedings of the National Academy of Sciences of new data supporting the use of the Company's ghrelin receptor antagonist compound, AEZS-123, for the treatment of alcohol dependence. August - Keryx, the Company's partner and licensee for perifosine in the North American market, reached an agreement with the FDA regarding a Special Protocol Assessment on the design of a Phase 3 trial with perifosine Keywords: Biopharmaceuticals, Biotechnology Business, Biotechnology Company, Clinical Oncology, Clinical Trial Research, Colon Cancer, Colon Carcinoma, Drugs, Endocrinology, Hematology, Keryx Biopharmaceuticals, Kidney, Lung Neoplasms, Lymphoma, Nephrology, Oncology, Pharmaceutical Business, Pharmaceutical Company, Pharmaceuticals, Small Cell Lung Cancer, Solid Cancers, Solid Carcinomas, Therapies, Aeterna Zentaris INC. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
